Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps

Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

This study evaluated the potential benefits of postoperative oral corticosteroids on surgical outcomes in CRSwNP patients and investigated the differential effects on eosinophilic CRSwNP (ECRSwNP) and noneosinophilic CRSwNP (NECRSwNP).Materials and methodsPatients with bilateral CRSwNP who underwent ESS were enrolled and randomized to receive either oral prednisolone (30 mg/day) or placebo for 2 weeks after surgery. Visual analog scale (VAS) and Sino-Nasal Outcome Test 22 (SNOT-22) scores were chosen as the subjective outcomes, evaluated at preoperative baseline and 1, 3, and 6 months postoperatively. Lund-Kennedy En...
Source: American Journal of Otolaryngology - Category: Endocrinology Source Type: research
ić D Abstract Clara cell protein 16 (CC16) is a small protein mainly produced by non-ciliated Clara cells in the respiratory epithelium. It has an anti-inflammatory role in chronic upper and lower airway eosinophilic inflammations. Decreased levels of CC16 are found in the nasal secretions and plasma of patients with chronic eosinophilic inflammatory disorders, such as asthma, allergic rhinitis, and chronic rhinosinusitis with or without nasal polyps, as well as in people exposed to high levels of air pollutants. Intranasal corticosteroid administration suppresses chronic inflammation of the nasal mucosa driven b...
Source: Arhiv za Higijenu Rada i Toksikologiju - Category: Occupational Health Authors: Tags: Arh Hig Rada Toksikol Source Type: research
Date: September 10, 2018 Issue #:  1555Summary:  The FDA has approvedSinuva (Intersect ENT), a sinus implant that gradually releases the corticosteroid mometasone furoate over a 90-day period, for treatment of nasal polyps in adults who have had ethmoid sinus surgery.Propel, a sinus implant that releases mometasone furoate over 30 days, is FDA-approved to maintain the sinus opening after ethmoid sinus surgery; it is marketed by the same manufacturer asSinuva.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: Topical corticosteroid usage in CRS patients in GP practices in Germany is as low as in other Western countries. Increased usage of topical corticosteroids in CRS patients with polyposis should be encouraged in GP and ENT practices. PMID: 30076702 [PubMed - as supplied by publisher]
Source: Rhinology - Category: ENT & OMF Tags: Rhinology Source Type: research
ConclusionOur prospective findings validate the potential value of sinus CT scan in predicting GC-sensitivity in CRSwNP patients.
Source: Clinical and Translational Allergy - Category: Allergy & Immunology Source Type: research
CONCLUSIONS: This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient distribution of this study does not necessarily reflect disease distribution in the general population. PMID: 29911211 [PubMed - as supplied by publisher]
Source: Rhinology - Category: ENT & OMF Tags: Rhinology Source Type: research
Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Abstract To evaluate the efficacy of a dermoplasty technique in controlling nasal polyps comparing to the conventional endoscopic approach. Prospective observational study Tertiary private hospital. Twenty-nine patients underwent surgery for replacement of the middle meatus mucosa with skin. Some patients (41.4%) suffered from allergies, 44.8% from asthma, and 27.6% from aspirin intolerance. Polyps were staged according to the Lildholdt system, and patients completed a sino-nasal outcome test (SNOT-22) pre and post-operatively. Also, patients were interrogated as for medication relevant to the nose received pre and post-...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - Category: ENT & OMF Source Type: research
Conclusion: To our knowledge, our study discusses the factors involved in the pathogenesis, clinical symptoms, diagnosis, treatment, and management of patients. This review can provide recommended strategies in a comprehensive and targeted vision for patients suffering from this syndrome.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
Intersect ENT, based in Menlo Park, California, is releasing in the U.S. its SINUVA sinus implant for treating nasal polyp disease in adults that underwent previous surgical sinus procedures. The device elutes mometasone furoate, a corticosteroi...
Source: Medgadget - Category: Medical Devices Authors: Tags: ENT Source Type: blogs
More News: Corticosteroid Therapy | Flonase | Flovent | Pharmaceuticals | Polyps